{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8021658_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"175-999-638-420-307"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11974,"type":"PATENT","title":"Thomas Jefferson University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2794,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8543,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Jefferson Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2672
Search Applicants and Owners separately:Jefferson Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2672
wherein said human VEGF peptide comprises an amino acid sequence unique to said alternative splice form,\n
wherein the peptide comprises no more than seven contiguous amino acids from a normally spliced product of a VEGF gene, and\n
wherein the alternative splice form is produced from a VEGF gene."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the immune response is an MHC HLA-class I or class II restricted cytotoxic T lymphocyte response, or an antibody response."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the cytotoxic T lymphocyte response is a CD8+ T lymphocyte response wherein CD8+, MHC class I-restricted T lymphocytes are activated."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the cytotoxic T lymphocyte response is a CD4+ T lymphocyte response wherein CD4+, MHC class II-restricted T lymphocytes are activated."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein one L-amino acid of the peptide is replaced with a D-amino acid."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein two or more peptides are administered to the subject."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the two or more peptides comprise a multimer."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein the multimer is a homomultimer."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8, wherein the multimer is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the multimer is a dimer."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein the multimer is a heteromultimer."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein the multimer is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the two or more peptides comprise an admixture."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the two or more peptides comprise overlapping epitopes from one or more alternative splice forms."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the at least one peptide is administered to the subject in combination with peptides that present T-helper cell epitopes."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the at least one peptide is administered to the subject in combination with at least one component that primes cytotoxic T lymphocytes."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein the at least one component that primes cytotoxic T lymphocytes comprises tripalmitoyl-S-glycerylcysteinly-seryl-serine (P3CSS)."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount is about 1 microgram to about 2,000 mg of the at least one peptide per 70 kg of subject."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount is about 1 microgram to about 500 mg of the at least one peptide per 70 kg of subject."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount is about 10 micrograms to about 200 mg of the at least one peptide per 70 kg of subject."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount is about 50 micrograms to about 100 mg of the at least one peptide per 70 kg of subject."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount of the at least one peptide is administered in a single dose."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount of the at least one peptide is administered in multiple doses."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount of the at least one peptide is administered enterally."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 24, wherein the enteral route of administration is selected from the group consisting of oral; rectal; and intranasal."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount of the at least one peptide is administered parenterally."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein the parenteral route of administration is selected from the group consisting of intravenous; intramuscular; intraarterial; intraperitoneal; intravaginal; intravesical; intradermal; intrapulmonary; inhalation; topical; subcutaneous; and instillation into the body."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the at least one peptide is administered to a subject in combination with a carrier or adjuvant."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 28, wherein the carrier is selected from the group consisting of keyhole limpet hemocyanin; thyroglobulin; albumins; tetanus toxoid; and polyamino acids."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 28, wherein the adjuvant is selected from the group consisting of complete Freund's adjuvant; incomplete Freund's adjuvant; aluminum phosphate; aluminum hydroxide; polylecithins; emulsified oils; and alum."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the at least one peptide is administered to a subject in combination with an immunostimulatory compound."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 31, wherein the immunostimulatory compound is selected from the group consisting of cytokines and haptens."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 32, where the cytokines are selected from the group consisting of GM-CSF; IL-12; IL-2; IL-4; IL-1α; and IL-18."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the cancer is selected from the group consisting of acute promyelocytic leukemia; acute lymphoblastic leukemia; myeloblastic leukemia; uterine cancer; thyroid cancer; gastrointestinal cancer; dysplastic and neoplastic cervical epithelium; melanoma; endometrial cancer; teratocarcinoma; colon cancer; desmoplastic round cell tumors; gastric cancer; breast cancer; ovarian cancer; prostate cancer; lung cancer; skin cancer; lymphoma; bladder cancer; and pancreatic cancer."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said administering at least one peptide to a subject comprises the steps of:\n
(1) removing immune system effector cells from a subject;\n
(2) maintaining the immune system effector cells in culture outside the body of the subject;\n
(3) optionally enriching the immune system effector cells for a particular immune system effector cell type;\n
(4) treating the cultured immune system effector cells with the at least one peptide;\n
(5) optionally examining a portion of the treated immune system effector cells to confirm the presence of the at least one peptide within the cells; and\n
(6) reintroducing the treated immune system effector cells into the subject."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 35, wherein treatment of the immune system effector cells with the at least one peptide comprises direct exposure of the cells to the at least one peptide."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 35, wherein the treated immune system effector cells are reintroduced into the subject by intravenous infusion or direct injection into the bone marrow."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 35, wherein about 105 to about 108 treated immune system effector cells per kilogram of subject body weight are reintroduced into the subject."],"number":38,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}